Last reviewed · How we verify
NCT00130494
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Phase 3 trial testing Zoledronic acid in Breast Cancer in 97 participants. Terminated before completion.
20 November 2006
Quick facts
| Lead sponsor | Spanish Breast Cancer Research Group |
|---|---|
| Phase | Phase 3 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 97 |
| Start date | 29 August 2002 |
| Primary completion | 20 November 2006 |
| Estimated completion | 22 October 2007 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Zoledronic acid (ZOLEDRONIC ACID) — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Neoplasm Metastasis — all drugs for Neoplasm Metastasis →
Sponsor
Spanish Breast Cancer Research Group
Who can join
Adults 18 to 70, female only, with Breast Cancer or Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, randomized, multicenter phase III trial to assess the efficacy of early administration of zoledronate versus observation in delaying bone-related symptoms in metastatic breast cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00130494
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zoledronic acid
Trials testing the same drug.
- NCT06374459 — Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Br · Phase 1, PHASE2 · recruiting
- NCT06135298 — FARE Augmentation of Proximal Femoral Fractures With CaS/HA and Systemic ZA · Phase 4 · completed
- NCT05866172 — HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC · Phase 3 · unknown
- NCT06051344 — Effect of Zoledronic Acid in Primary Knee Osteoarthritis · Phase 4 · unknown
- NCT05405894 — Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Spanish Breast Cancer Research Group trials
Trials by the same sponsor.
- NCT07478939 — Study on the Level of Physical Activity in Patients Diagnosed With Breast Cancer in Spain · completed
- NCT05744375 — Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab · Phase 2 · terminated
- NCT05583110 — Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non · Phase 2 · terminated
- NCT04293393 — Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients · Phase 2 · active not recruiting
- NCT03800355 — Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00130494 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spanish Breast Cancer Research Group
- Last refreshed: 16 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00130494.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing